Technology Potential
Projected Earnings from the BioClonetics’ passive immunotherapy have been calculated by an independent national consulting firm. This analysis examines the expected potential profits from 2 perspectives: (1) considering sales only to North Americ and Western Europe and (2) considering sales to the major Markets including North America, Western and Central Europe, Eastern Europe and Central Asia, South and Southeast Asia and Latin America. These potential earnings and underlying assumptions are set forth here:
Potential Profit from Technology
Assumptions for Graph 1 - passive immunotherapy
Approximately 2.3 million potential patient populations with HIV/AIDS (North American and Western Europe) [1]
· Assumes 1.5% annual increase in population growth over the forecast period
· $8,000 treatment total cost per patient (single series of treatments for one year)
· Assumes penetration of from 1% in year one to maximum of 15%
· Assumes a reduction in the population group by the number treated
· Cost of antibody - $2400 ($100 for 24 treatments) –(actual cost of production to the Company of the antibody is expected to be far less than this very conservative estimate)
[1] https://www.aids.gov/hiv-aids-basics/hiv-aids-101/global-statistics/; UNAIDS Global Report on the AIDS Epidemic
Assumptions for Graph 2 – passive immunotherapy – 7 Major Markets
Patient Population:
Major Markets – HIV population[1]
North America – 2.3 million
Western and Central Europe - .85 million
Eastern Europe and Central Asia – 1.1 million
South and Southeast Asia (including India) – 4.8 million
Latin America – 1.6 million
Total – 10.65 million
Assumes 9.55 million potential patient populations with HIV/AIDS
· Assumes 1.5% annual increase in potential population growth over the forecast period
· $8,000 treatment total cost per patient (single series of treatments for one year only)
· Assumes penetration of from 1% in year one to maximum of 15%
· Assumes a reduction in the population group by the number treated
[1] https://www.aids.gov/hiv-aids-basics/hiv-aids-101/global-statistics/; UNAIDS Global Report on the AIDS Epidemic
A vaccine against HIV has a much broader application and will produce significantly larger earnings.
An HIV vaccine.
[1] https://www.aids.gov/hiv-aids-basics/hiv-aids-101/global-statistics/; UNAIDS Global Report on the AIDS Epidemic
Assuming a penetration rate of 1% rising to a maximum 15% over a five-year period, aggregate profit in the first 10 years from treating HIV- infected individuals in the U.S. and Western Europe would be $ 17.33 billion.